Brisbane, CA, United States
Brisbane, CA, United States

Time filter

Source Type

Patent
Intermune Inc. | Date: 2016-12-01

The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.


Patent
InterMune Inc. | Date: 2017-03-22

The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.


Patent
Intermune Inc. | Date: 2015-08-20

A process for synthesizing pirfenidone from bromobenzene having less than about 0.15% by weight dibromobenze is disclosed. Also disclosed are processes of synthesizing pirfenidone without using ethyl acetate or n-butanol, and pirfenidone having controlled levels of ethyl acetate, n-butanol, di(5-methyl-2-pyridinone)benzenes, and other impurities having specified retention times. Also disclosed are formulated dosage forms including the disclosed pirfenidone.


Patent
Intermune Inc. | Date: 2016-07-18

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.


Patent
InterMune Inc. | Date: 2016-05-23

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.


A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.


Patent
Intermune Inc. | Date: 2016-05-06

Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.


Patent
InterMune Inc. | Date: 2016-08-10

The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.


Patent
Intermune Inc. | Date: 2016-04-13

The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.


Patent
Intermune Inc. | Date: 2016-06-10

The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.

Loading InterMune Inc. collaborators
Loading InterMune Inc. collaborators